Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (October 2024)
26 slides from Island Pharmaceuticals's investor presentation, Oct 8, 2024
Slide 1: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS DR DAVID FOSTER, MANAGING DIRECTOR 8 October 2024 (ASX: ILA) ISLAND PHARMACEUTICALS 1 October 2024
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 3: Island Pharmaceuticals is an antiviral therapeutics company targeting infectious diseases
For personal use only Island Pharmaceuticals (ASX:ILA) is an antiviral therapeutics company targeting infectious diseases ISLAND PHARMACEUTICALS 3 October 2024
Slide 4: Assets: rapid paths to market
For personal use only ASSETS: - Known small molecules with clinical history - Mid/late stage clinical or other abbreviated routes - Open USFDA INDs - Validated US Govt/military funding support - Priority Review Voucher eligible RAPID PATHS TO MARKET ISLAND PHARMACEUTICALS 4 October 2024
Slide 5: Island at a glance
ISLAND AT A GLANCE For personal use only Dengue infects up to Major market Positive results in 400m per year* potential aggressive models Now endemic in more than 100 ISLA-101 has potential to address In animal and human cellular countries with no current mosquito-borne diseases, which are models of
Slide 6: Dengue is a widespread issue
DENGUE IS A WIDESPREAD ISSUE For personal use only Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands HealthMap: recent reports of local or imported dengue cases https://www.healthmap.org/dengue/en - visited September 26,,
Slide 7: Dengue in 2050 – a global disease
DENGUE IN 2050 – A GLOBAL DISEASE For personal use only Prediction based on projections of future temperatures, rainfall, and mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.nasa.
Slide 8: Infection and spread
INFECTION AND SPREAD For personal use only Why the surge in dengue infections? Uninfected mosquito Warmer temperatures • Accelerate development • Increase activity of female mosquitoes • Reduce incubation time for mosquito to become Mosquito bites infectious 1-14 day How dengue infected person • All
Slide 9: About half of the world's population is at risk of dengue
For personal use only “About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 30 May 2024 ISLAND PHARMACEUTICALS 9 October 2024
Slide 10: About ISLA-101
For personal use only About ISLA-101 ISLAND PHARMACEUTICALS 10 October 2024
Slide 11: ISLA-101 broad activity evident
ISLA-101 BROAD ACTIVITY EVIDENT For personal use only Demonstrated activity against flaviviruses (a subgroup of arboviruses) in multiple models of infection • In in-vitro models ISLA-101 has demonstrated broad anti-viral activity Dengue • In in-vitro models using fresh human cells, ISLA-101 has 1-4
Slide 12: ISLA-101 prevents viral replication
ISLA-101 PREVENTS VIRAL REPLICATION For personal use only Mechanism of action (how it works) ISLA-101 reduces viral load1 ISLA-101 inhibits propagation of flaviviruses Above: dose response showing ISLA-101’s ability to protect against dengue infection • To replicate, the virus needs to hijack the nu
Slide 13: Prevents animal deaths from lethal dengue
PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE For personal use only ISLA-101 has also been shown to be protective in animal models of both dengue and Zika Virus. Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISL
Slide 14: Phase 2a/b dengue (PROTECT) trial study
PHASE 2a/b DENGUE (PROTECT) TRIAL STUDY For personal use only “PROTECT" study- A Phase 2a/b, Randomized, Double Phase 2a/b trial protocol: 2 cohorts blind, Placebo-controlled Dengue Challenge Study – a 1. Prophylactic Cohort- 2A: 4 subjects randomized 3:1 PROphylactic and TrEatment Challenge Trial 2
Slide 15: Why a challenge study?
WHY A CHALLENGE STUDY? For personal use only “When there are no available animal models of a disease, researchers take a weakened form of the virus and create a mild, safe form of the disease in a healthy person. The idea is that in a safe, well-controlled environment using a small number of people,
Slide 16: Phase 2a/b clinical trial design
PHASE 2a/b CLINICAL TRIAL DESIGN For personal use only Phase 2a/b trial protocol: 2 cohorts Key near-term milestones: 1. Prophylactic Cohort- 2a (left): 4 subjects randomized 3:1 • Ethics approval received in August 2024, patient 2. Therapeutic Cohort: 2b (right): 10 subjects randomized 8:2 screenin
Slide 17: Phase 1 control data demonstrates benefit of challenge study approach
PHASE 1 CONTROL DATA DEMONSTRATES BENEFIT OF CHALLENGE STUDY APPROACH For personal use only A Phase 1 challenge study conducted by Walter Reed and SUNY Upstate forms the basis of Island’s PEACH study control data, and enabled unprecedented ability to monitor dengue symptoms, including: • Abdominal p
Slide 18: Strategic checklist
STRATEGIC CHECKLIST For personal use only Clinical history Small molecule Proven preclinical anti-viral activity Eligible for Priority Review Vouchers National and military preparedness need Probable/confirmed non-dilutive funding to support: military, civilian, NGO Fit for our managem
Slide 19: Pipeline build, opportunities and milestones
For personal use only PIPELINE BUILD, OPPORTUNITIES AND MILESTONES ISLAND PHARMACEUTICALS 19 October 2024
Slide 20: Targeting known or re-purposable drugs with reduced time to market
TARGETING KNOWN OR RE-PURPOSABLE DRUGS WITH REDUCED TIME TO MARKET For personal use only GALIDESIVIR – Ebola, Marburg, Zika & and many other RNA viruses • 12 month, binding Letter of Intent signed 11 September 2024 • Substantial Phase I human safety data • Proven protective efficacy in a number of l
Slide 21: Commercial opportunities
COMMERCIAL OPPORTUNITIES BOTH candidates have prophylactic and therapeutic potential For personal use only Travellers Military National Outbreaks Malaria is also a mosquito borne Relationship with US Army in Millions of patients in Latin disease and therefore a proxy for place (CRADA, ISLA101). Will
Slide 22: Well-funded for key inflection points
WELL-FUNDED FOR KEY INFLECTION POINTS For personal use only • Island has secured A$3.5m in new funding to support key inflection points in our clinical program and our pipeline build “I have been invested in Island for many years and have been watching the company closely • Two-tranche placement at
Slide 23: Corporate snapshot
CORPORATE SNAPSHOT Key data Recent ILA trading history For personal use only Share price (AUD1) $0.135 Market cap1 $16.35m Shares on issue1 154,111,068 Listed Options2 32,384,597 Cash at 30 June 20243 $1.7m Placement announced 3 October 2024 $3.5m Board of Directors DoD grant funding to directly sup
Slide 24: Key milestones
KEY MILESTONES** For personal use only H1 FY 2025 H1 FY 2024 (Jul – Dec 2023) H2 FY 2024 (Jan – Jun 2024) H2 FY 2025 (Jan – Jun 2025) (Jul – Dec 2024) • Key US and Australian • Dose final Single • Obtain ethics approval • Subjects dosed in patents granted for Ascending Dose for Phase 2 trial Phase 2
Slide 25: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 25 October 2024
Slide 26: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD For personal use only Dr Leigh Farrell Prof Stephen Thomas MD Dr Amy Patick Leigh has over 30 years’ experience in the US WRAIR – SUNY Upstate BMS – Mayo Clinic biotechnology and pharmaceutical industry and is Professor Stephen Thomas, MD has an international Amy Patick is
Island Pharmaceuticals — Investor Presentation (October 2024) on 6ix